• Info
  • Significant Ownership

Significant Ownership of Invus Global Management, LLC

Signature - Title
/s/ Raymond Debbane - Raymond Debbane, President
Location
New York, NY
Summary
This page shows a list of all the recent SCHEDULE 13D/G filings made by Invus Global Management, LLC.

Notify me when Invus Global Management, LLC files a new Schedule 13D/G report.

⭐ Subscribe ⭐

Significant Ownership of Invus Global Management, LLC

Sym Company Class Ownership Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
SRRK Scholar Rock Holding Corporation Common Stock, par value $0.001 per share 11% $292,924,852 10,825,013 Invus Public Equities, L.P. 31 Dec 2024
IVA Inventiva S.A. Ordinary shares, nominal value Euro 0.01 per share 11% $51,999,994 +$25,999,999 14,814,813 +100% Invus Public Equities, L.P. 30 Jun 2025
RANI Rani Therapeutics Holdings, Inc. Class A Common Stock, $0.0001 par value 10% $4,910,990 9,825,911 Raymond Debbane 16 Oct 2025
BCAX Bicara Therapeutics Inc. Common Stock, par value $0.0001 per share 9.6% $68,029,276 5,216,969 Raymond Debbane 30 Jun 2025
SLDB Solid Biosciences Inc. Common Stock, $0.001 par value per share 9.6% $20,022,944 +$9,900,533 7,415,905 +98% Raymond Debbane 31 Mar 2025
VTVT vTv Therapeutics Inc. Class A Common Stock, $0.01 par value per share 9.4% $9,181,040 +$1,051,352 393,098 +13% Raymond Debbane 30 Sep 2025
TENX Tenax Therapeutics, Inc. Common Stock, $0.0001 par value per share 9.4% $2,562,846 427,141 Raymond Debbane 26 Sep 2025
NBTX Nanobiotix S.A. Ordinary shares, nominal value Euro 0.03 per share 8.9% $13,333,411 4,232,829 Invus Public Equities, L.P. 31 Dec 2023
ABVX Abivax S.A. Ordinary shares, nominal value Euro 0.01 per share 8.5% $32,099,671 5,403,985 Invus Public Equities, L.P. 02 Sep 2022
DBVT DBV Technologies S.A. Ordinary Shares, nominal value Euro 0.10 per share 7.8% $115,384,600 11,538,460 Raymond Debbane 06 Oct 2025
RZLT Rezolute, Inc. Common Stock, $0.001 par value per share 5.4% $34,090,000 4,870,000 Raymond Debbane 18 Sep 2025
TNGX Tango Therapeutics, Inc. Common Stock, $0.001 par value per share 5.3% $40,593,997 5,883,188 Raymond Debbane 19 Sep 2025
VIGL Vigil Neuroscience, Inc. Common Stock, par value $0.0001 per share 4.9% $2,966,647 1,991,038 Raymond Debbane 31 Dec 2024
SYRS Syros Pharmaceuticals, Inc. Common Stock, $0.001 par value per share 3.8% $776,595 1,063,829 Invus Public Equities, L.P. 31 Dec 2024
GOSS Gossamer Bio, Inc. Common Stock, par value $0.0001 per share 2.8% $4,881,926 6,258,880 Invus Public Equities, L.P. 31 Dec 2024
KLRS Kalaris Therapeutics, Inc. Common Stock, $0.0001 par value per share 1.5% $955,141 282,586 Invus Public Equities, L.P. 30 Jun 2025

Schedules 13D/G Reported by Invus Global Management, LLC:

Sym Target Class Ownership Change Current Shares Change Value Reporting name Form Report Period Filing Date
* An asterisk sign (*) next to the price indicates that the price is likely invalid.